Asuka Pharmaceutical has decided to transition to a company with a Corporate Auditor Committee, revising the director compensation system and introducing a system for outside directors. The revision is subject to shareholder approval, reviewing compensation amounts and stock grant conditions to strengthen incentives for corporate value enhancement and promote value sharing with shareholders.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Inc.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4886-20260525-02.pdf","jir_short_summary":"Asuka Pharmaceutical has decided to transition to a company with a Corporate Auditor Committee, revising the director compensation system and introducing a system for outside directors. The revision is subject to shareholder approval, reviewing compensation amounts and stock grant conditions to strengthen incentives for corporate value enhancement and promote value sharing with shareholders.","jir_summary":"### Outline of the System Revision\nAsuka Pharmaceutical has reviewed its director compensation system in conjunction with transitioning to a company with a Corporate Auditor Committee. The revision includes partial modifications to the stock reward system with transfer restrictions for targeted directors and the introduction of a new performance-linked compensation system. This aims to enhance incentives for directors to improve corporate value and promote value sharing with shareholders. The system revision requires shareholder approval at the general meeting, with upper limits set for compensation amounts and stock grants.\n\n### System Implementation and Future Outlook\nBy introducing the new system, conditions for director compensation and stock grants are expected to become clearer, with increased linkage to performance. Similar systems will be introduced for outside directors to strengthen management oversight functions. These measures are aimed at sustainable corporate value improvement and maximizing shareholder value, positioned as part of future management strategies.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#AsukaPharmaceutical, #IRType, #JapaneseStocks","jir_key_figures":"Total reward upper limit: within 140 million yen per year (combined for tenure-based and performance-based systems)\nStock grant upper limit: 140,000 shares per year (70,000 shares for tenure-based, 70,000 shares for performance-based)\nTarget directors: all directors and outside directors to implement the system","jir_meta_title":"[Asuka Pharmaceutical] Revision and Transition of Director Compensation System | May 2026","jir_meta_description":"Asuka Pharmaceutical is planning to revise its director compensation system and introduce a system for outside directors following its transition to a company with a Corporate Auditor Committee. Implementation is subject to shareholder approval.","jir_og_title":"[Asuka Pharmaceutical] Revision and Transition of Director Compensation System | May 2026","jir_og_description":"Asuka Pharmaceutical has approved revisions to its director compensation system and system introduction. Aiming for corporate value enhancement and maximum shareholder value.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-54414","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n